{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:36:21Z","timestamp":1789590981582,"version":"build-2803163510"},"reference-count":60,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":8766,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Law. Med. Ethics"],"published-print":{"date-parts":[[1997]]},"abstract":"<jats:p>In the past twelve to eighteen months, another perceived threat to the safety of America's blood supply has arisen. The fear is that Creutzfeldt-Jakob disease (CJD) will join hepatitis, HW and AIDS in the public and medical consciousness as the 1990s next infectious disease epidemic. A particular kind of ethical dilemma has arisen causing much debate and consternation for hospitals, regulators, and blood suppliers, and has elicited a remarkably varied response.<\/jats:p><jats:p>CJD is a rare but uniformly fatal neurological disease: it affects the brain and the rest of the central nervous system. Its incidence in the population of the developed world is about one per million per year, although some geographic anomalies exist. CJD manifests itself in two broad ways. First, the disease is associated with symptoms of mental deterioration and dementia, including memory loss, anxiety, and cognitive impairment. Second, CJD is also associated with a range of neurological symptoms, including muscle rigidity, seizures, tremors, muscle twitching, and spasticity, as well as problems with muscle coordination and unsteady gait, sometimes resulting in total disability.<\/jats:p>","DOI":"10.1111\/j.1748-720x.1997.tb01394.x","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T12:18:45Z","timestamp":1181045925000},"page":"34-41","source":"Crossref","is-referenced-by-count":6,"title":["Creutzfeldt-Jakob Disease: The Problem of Recipient Notification"],"prefix":"10.1017","volume":"25","author":[{"given":"Gordon","family":"DuVal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"key":"S1073110500004137_ref06","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/brain\/101.2.333","article-title":"\u201cSubacute Spongiform Encephalopathy (Creutzfeldt-Jakob Disease): The Nature and Progression of Spongiform Change,\u201d","volume":"101","author":"Masters","year":"1978","journal-title":"Brain"},{"key":"S1073110500004137_ref030","unstructured":"30. Immen, W. , \u201cHospital Warns Parents of Blood Risk,\u201d Globe and Mail (Toronto), May 4, 1996, at A1."},{"key":"S1073110500004137_ref033","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajmg.1320480412","article-title":"\u201cRisk Factors for Suicide in Huntington's Disease,\u201d","volume":"48","author":"Lipe","year":"1993","journal-title":"American Journal of Medical Genetics"},{"key":"S1073110500004137_ref035","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajmg.1320540304","article-title":"\u201cPsychological Costs and Benefits of Predictive Testing for Huntington's Disease,\u201d","volume":"54","author":"Codori","year":"1994","journal-title":"American Journal of Medical Genetics"},{"key":"S1073110500004137_ref039","doi-asserted-by":"crossref","unstructured":"39. In re Sealed Case, 61 F.3d 965 (D.C. Cir. 1995).","DOI":"10.1016\/S0001-2092(06)63797-6"},{"key":"S1073110500004137_ref05","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1992.tb00909.x"},{"key":"S1073110500004137_ref042","unstructured":"42. Arato v. Avedon, 858 P.2d 598, 605 (Cal. 1993) (noting duty to disclose \u201cdire prognosis\u201d)."},{"key":"S1073110500004137_ref051","unstructured":"51. American College of Legal Medicine, Legal Medicine (St. Louis: Mosby, 3rd ed., 1995): At 283."},{"key":"S1073110500004137_ref024","unstructured":"24. Information Letter from Health Canada (Oct. 20, 1995) (on file with author)."},{"key":"S1073110500004137_ref011","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a072655"},{"key":"S1073110500004137_ref017","unstructured":"17. See Manuelidis, , supra note 7."},{"key":"S1073110500004137_ref016","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jama.1991.03460070062043","article-title":"\u201cCreutzfeldt-Jakob Disease in Pituitary Growth Hormone Recipients in the United States,\u201d","volume":"265","author":"Fradkin","year":"1991","journal-title":"JAMA"},{"key":"S1073110500004137_ref059","volume-title":"Remarks at Meeting \u201cCreutzfeldt-Jakob Disease: Decision-Making in Conditions of Uncertainty,\u201d","author":"McLelland","year":"1996"},{"key":"S1073110500004137_ref046","unstructured":"46. M.M.H. v. United States, 966 F.2d 285 (7th Cir. 1992)."},{"key":"S1073110500004137_ref010","doi-asserted-by":"crossref","DOI":"10.1001\/archneur.1976.00500040036005","article-title":"\u201cFamilial Neurological Disease Associated with Spongiform Encephalopathy,\u201d","volume":"33","author":"Rosenthal","year":"1976","journal-title":"Archives of Neurology"},{"key":"S1073110500004137_ref034","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajmg.1320420416","article-title":"\u201cPredictive Testing for Huntington Disease in Canada,\u201d","volume":"42","author":"Bloch","year":"1992","journal-title":"American Journal of Medical Genetics"},{"key":"S1073110500004137_ref053","unstructured":"53. This is the manner of notification used, for example, by the Calgary Regional Health Authority and Toronto's Hospital for Sick Children."},{"key":"S1073110500004137_ref057","unstructured":"57. This is the method preferred by Health Canada. See Information Letter from Health Canada, Health Protection Branch (Oct. 20, 1995) (on file with author)."},{"key":"S1073110500004137_ref045","unstructured":"45. Union Carbide & Carbon Corp. v. Stapleton, 237 F.2d 229 (6th Cir. 1956)."},{"key":"S1073110500004137_ref031","unstructured":"31. I acknowledge that the analogy is not as persuasive as hoped. Aside from young children, those tested for Huntington disease already know that they are at some risk of developing the disease. The test simply makes the prognosis more or less certain. Notifying of possible CJD exposure introduces this risk to persons theretofore totally unaware of it."},{"key":"S1073110500004137_ref049","unstructured":"49. See id. at 554."},{"key":"S1073110500004137_ref023","unstructured":"23. Memorandum from the European Agency for the Evaluation of Medicinal Products (Feb. 13, 1995) (on file with author); and Position Paper or the European Association of the Plasma Products Industry (July 18, 1995) (on file with author)."},{"key":"S1073110500004137_ref047","unstructured":"47. Miles, 927 F.2d at 194\u201395."},{"key":"S1073110500004137_ref032","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/jmg.32.7.516","article-title":"\u201cEmotional and Functional Impact of DNA Testing on Patients with Symptoms of Huntington's Disease,\u201d","volume":"32","author":"Jankovic","year":"1995","journal-title":"Journal of Medical Genetics"},{"key":"S1073110500004137_ref043","unstructured":"43. 112 D.L.R.4th at 372."},{"key":"S1073110500004137_ref027","unstructured":"27. This point was raised by Rothman, David , Remarks at the Meeting \u201cCreutzfeldt-Jakob Disease: Decision-Making in Conditions of Uncertainty,\u201d Toronto (June 6, 1996) (on file with author)."},{"key":"S1073110500004137_ref055","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320570111"},{"key":"S1073110500004137_ref018","first-page":"3","article-title":"\u201cCurrent Status of Creutzfeldt-Jakob Disease and Blood Product Safety,\u201d","volume":"2","author":"Evatt","year":"1995","journal-title":"Haemophilia World"},{"key":"S1073110500004137_ref09","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1126\/science.6801762","article-title":"\u201cNovel Proteinaceous Infectious Particles Cause Scrapie,\u201d","volume":"216","author":"Prusiner","year":"1982","journal-title":"Science"},{"key":"S1073110500004137_ref060","volume-title":"Remarks at Meeting \u201cCreutzfeldt-Jakob Disease: Decision-Making in Conditions of Uncertainty,\u201d","author":"Paltiel","year":"1996"},{"key":"S1073110500004137_ref013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197706092962308"},{"key":"S1073110500004137_ref022","unstructured":"22. It was passed by a vote of six to five, with two abstentions, at a special meeting held on June 22, 1995. For a report of the proceedings, see Council of Community Blood Centers, supra note 20."},{"key":"S1073110500004137_ref020","unstructured":"20. Dodd, Roger , American Red Cross, Remarks at Special Meeting of Food and Drug Administration Special Advisory Panel on Creutzfeldt-Jakob Disease and Blood Products (June 22, 1995). See Council of Community Blood Centers, CCBC Newsletter, June 23, 1995, at 9\u201310."},{"key":"S1073110500004137_ref050","unstructured":"50. Spann v. Irwin Memorial Blood Centers, 40 Cal. Rptr. 2d 360 (Cal. Ct. App. 1995)."},{"key":"S1073110500004137_ref044","unstructured":"44. Daly v. United States, 946 F.2d 1467 (9th Cir. 1991)."},{"key":"S1073110500004137_ref056","unstructured":"56. This is the approach adopted by Winnipeg's Health Sciences Centre when it faced this dilemma. See Free Press (Winnipeg), May 11, 1996, at A2."},{"key":"S1073110500004137_ref015","doi-asserted-by":"crossref","unstructured":"15. Bernouilli, C. , \u201cDanger of Accidental Person-to-Person Transmission of Creutzfeldt-Jakob Disease by Surgery,\u201d Lancet, (1977): 478\u201379.","DOI":"10.1016\/S0140-6736(77)91958-4"},{"key":"S1073110500004137_ref048","unstructured":"48. Hoemke v. New York Blood Center, 912 F.2d 550 (2d Cir. 1990)."},{"key":"S1073110500004137_ref038","unstructured":"38. 927 F.2d 187."},{"key":"S1073110500004137_ref037","unstructured":"37. For example, Christopher v. Cutter Laboratories, 53 F.3d 1184 (11th Cir. 1995) (alleging that the defendant supplier of blood products failed to warn prior to the transfusion that might have transmitted HIV to the hemophiliac patient)."},{"key":"S1073110500004137_ref025","unstructured":"25. Letter from Dr. Aye, Bert , National Director of Blood Services, to all Blood Bank directors and chief executive officers (July 17, 1995) (on file with author); and Memorandum from Dr. Aye, Bert , National Director of Blood Services, to all Blood Bank directors and chief executive officers (July 24, 1995) (on file with author)."},{"key":"S1073110500004137_ref014","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1988.69.5.0766"},{"key":"S1073110500004137_ref07","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1046\/j.1537-2995.1994.341095026981.x","article-title":"\u201cThe Dimensions of Creutzfeldt-Jakob Disease,\u201d","volume":"34","author":"Manuelidis","year":"1994","journal-title":"Transfusion"},{"key":"S1073110500004137_ref058","unstructured":"58. Pittman Estate v. Bain suggests that it may not. See Pittman, 112 D.L.R.4th at 382\u201383."},{"key":"S1073110500004137_ref01","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410050212"},{"key":"S1073110500004137_ref041","unstructured":"41. 927 F.2d at 193; and 112 D.L.R.4th at 310."},{"key":"S1073110500004137_ref08","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a072644"},{"key":"S1073110500004137_ref054","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1939-0025.1987.tb03531.x","article-title":"\u201cPsychiatric Implications of Presymptomatic Testing for Huntington's Disease,\u201d","volume":"51","author":"Kessler","year":"1987","journal-title":"American Journal of Orthopsychiatry"},{"key":"S1073110500004137_ref02","unstructured":"2. See id. For example, Creutzfeldt-Jakob disease (CJD) is known to have a higher incidence among Libyan Jews and in Slovakia, Italy, and Chile."},{"key":"S1073110500004137_ref04","volume-title":"Canada Communicable Disease Report","year":"1996"},{"key":"S1073110500004137_ref012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0140-6736(92)92431-E","article-title":"\u201c\u2018Friendly Fire\u2019 in Medicine: Hormones, Homografts, and Creutzfeldt-Jakob Disease,\u201d","volume":"340","author":"Brown","year":"1992","journal-title":"Lancet"},{"key":"S1073110500004137_ref028","unstructured":"28. In addition, in the event that life or health insurance companies include questions about exposure to CJD in application questionnaires, those notified may find life or health insurance either unavailable or more expensive."},{"key":"S1073110500004137_ref019","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0140-6736(93)90068-R","article-title":"\u201cCreutzfeldt-Jakob Disease and Blood Transfusion,\u201d","volume":"341","author":"Esmonde","year":"1993","journal-title":"Lancet"},{"key":"S1073110500004137_ref021","unstructured":"21. This was reported at a meeting on December 15\u201316, 1994. See \u201cBPAC Recommends Component Retrieval for Previous Donations from CJD-Infected Donors,\u201d AABB Blood Bank Week, 11, no. 45 (1994)."},{"key":"S1073110500004137_ref036","unstructured":"36. See, for example, Stanback v. Parke, Davis & Co., 657 F.2d 642 (4th Cir. 1981); Doe v. Miles Laboratories, 927 F.2d 187 (4th Cir. 1991); and Tarasoff v. Regents of the University of California, 551 P.2d 334 (Cal. Sup. Ct. 1976)."},{"key":"S1073110500004137_ref026","unstructured":"26. For example, the Hospital for Sick Children in Toronto and the Calgary Regional Health Authority both undertook notification campaigns. However, Vancouver General Hospital, Alberta Capital Health Authority, and Winnipeg's Health Sciences Centre have each decided not to notify specific recipients."},{"key":"S1073110500004137_ref052","unstructured":"52. Miceikis v. Field, 347 N.E.2d 320, 324 (Ill. App. Ct. 1976) (\u201cexcessive disclosure of remote risks would tend to do more harm than good to the patient\u201d); see also, Pardy v. United States, 783 F.2d 710 (7th Cir. 1986); and McInerney v. McDonald [1992] 93 D.L.R.4th 415, 429\u201330 (Can.)."},{"key":"S1073110500004137_ref029","unstructured":"29. Walker, R. , \u201cBlood Recipients Joining Forces,\u201d Herald (Calgary), May 1, 1996, at B1."},{"key":"S1073110500004137_ref040","unstructured":"40. See id.; and Pittman Estate v. Bain [1994] 112 D.L.R.4th 257, 403\u201312 (Ont. High Ct.)."},{"key":"S1073110500004137_ref03","article-title":"\u201cThe Clinical Characteristics of Transmissible Creutzfeldt-Jakob Disease,\u201d","volume":"96","author":"Roos","year":"1973","journal-title":"Brain"}],"container-title":["Journal of Law, Medicine &amp; Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1748-720X.1997.tb01394.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1111\/j.1748-720X.1997.tb01394.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1073110500004137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:40:14Z","timestamp":1683870014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1073110500004137\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997]]}},"alternative-id":["S1073110500004137"],"URL":"https:\/\/doi.org\/10.1111\/j.1748-720x.1997.tb01394.x","relation":{},"ISSN":["1073-1105","1748-720X"],"issn-type":[{"value":"1073-1105","type":"print"},{"value":"1748-720X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997]]}}}